newsfilter
← Latest News
GlobeNewswire·

AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041

Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom Latest milestone further strengthens AIM’s expanding global Ampligen patent